In an­oth­er try at lung can­cer niche, J&J nabs a po­ten­tial Tagris­so ri­val for $50M-plus

Weeks af­ter bow­ing out of a bil­lion-dol­lar deal with Aduro Biotech, J&J is back to the draw­ing board with an­oth­er on­col­o­gy li­cens­ing pact that, if fruit­ful, could pit them di­rect­ly against As­traZeneca’s lung can­cer star Tagris­so.

Ko­re­an drug­mak­er Yuhan is col­lect­ing $50 mil­lion up­front on the deal, which cen­ters around laz­er­tinib, a third-gen­er­a­tion EGFR ty­ro­sine-ki­nase in­hibitor de­signed to tar­get mul­ti­ple mu­ta­tions of the re­cep­tor. With world­wide rights to the as­set — ex­cept for South Ko­rea — J&J will take over de­vel­op­ment, man­u­fac­tur­ing and com­mer­cial­iza­tion while col­lab­o­rat­ing with Yuhan on clin­i­cal tri­als.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.